Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021

View ORCID ProfileMarie C.D. Stoner, Frederick J. Angulo, Sarah Rhea, Linda Morris Brown, Jessica E. Atwell, Jennifer L. Nguyen, John McLaughlin, David L. Swerdlow, Pia D.M. MacDonald
doi: https://doi.org/10.1101/2021.09.17.21263759
Marie C.D. Stoner
aRTI International, Research Triangle Park, NC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie C.D. Stoner
  • For correspondence: mcstoner@rti.org
Frederick J. Angulo
bMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Rhea
aRTI International, Research Triangle Park, NC, United States
cDepartment of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Morris Brown
aRTI International, Research Triangle Park, NC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica E. Atwell
bMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. Nguyen
bMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John McLaughlin
bMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Swerdlow
bMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pia D.M. MacDonald
aRTI International, Research Triangle Park, NC, United States
dDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, NC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Information is needed to monitor progress toward a level of population immunity to SARS-CoV-2 sufficient to disrupt viral transmission. We estimated the percentage of the United States (US) population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021.

Methods Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention (CDC) were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates to a range of population immunity thresholds.

Results Presumed population immunity varied among states (43.1% to 70.6%), with 19 states with 60% or less of their population having been infected or vaccinated. Four states have presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (78% or higher).

Conclusions The US remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.

Summary As of August 26, 2021, no state has reached a population level of immunity thought to be sufficient to disrupt transmission. (78% or higher), with some states having remarkably low presumed immunity.

Competing Interest Statement

Frederick Angulo, Jessica Atwell, John McLaughlin, Jennifer Nguyen, and David Swerdlow are employees of and hold stock and stock options in Pfizer Inc.

Funding Statement

This work was supported by funding from Pfizer to RTI for data collection, analysis, and manuscript development by Marie Stoner, Sarah Rhea, Linda Brown and Pia MacDonald who are employees of RTI.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Exempt

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available by contacting the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
Marie C.D. Stoner, Frederick J. Angulo, Sarah Rhea, Linda Morris Brown, Jessica E. Atwell, Jennifer L. Nguyen, John McLaughlin, David L. Swerdlow, Pia D.M. MacDonald
medRxiv 2021.09.17.21263759; doi: https://doi.org/10.1101/2021.09.17.21263759
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
Marie C.D. Stoner, Frederick J. Angulo, Sarah Rhea, Linda Morris Brown, Jessica E. Atwell, Jennifer L. Nguyen, John McLaughlin, David L. Swerdlow, Pia D.M. MacDonald
medRxiv 2021.09.17.21263759; doi: https://doi.org/10.1101/2021.09.17.21263759

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)